Search clinical trials for: High dose Melphalan

Total 38162 results

Uppsala University
Dalarna County Council, Sweden; Uppsala County Council, Sweden

Not yet recruiting

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Myeloma Multiple
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia | Myeloproliferative Neoplasm | Pro-Lymphocytic Leukemia

United States
Christopher Strouse
University of Iowa

Recruiting

High Dose Ascorbic Acid for Plasma Cell Disorders

Multiple Myeloma

United States
Swedish Medical Center

Recruiting

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion (BEAM)

Multiple Myeloma

United States
Samsung Medical Center

Recruiting

Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor

Intracranial Non-germinomatous Germ Cell Tumor

Korea, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Refractory and/or Relapsed Metastatic Solid Tumors

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Non-Hodgkin's Lymphoma

United States
CASI Pharmaceuticals (China) Co., Ltd.

Completed

Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation

Multiple Myeloma

China
Rush University Medical Center

Completed

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Nausea | Vomiting

United States
Janssen Research & Development, LLC

Completed

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Multiple Myeloma

Korea, Republic of, Malaysia, China, Taiwan, Hong Kong
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Refractory Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Completed

High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

Neuroblastoma

United States
M.D. Anderson Cancer Center

Completed

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Testicular Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Myeloproliferative... and other conditions

United States
Hackensack Meridian Health

Terminated

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Spectrum Pharmaceuticals, Inc

Active, not recruiting

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

Multiple Myeloma | Amyloidosis

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
European Myeloma Network; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM... and other collaborators

Active, not recruiting

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (HO95)

Multiple Myeloma

Sweden, Norway, Italy, Netherlands, Belgium, Switzerland, Australia, Denmark, Finland, Czechia, Turkey, Austria, Luxembourg, Hungary, Greece, Portugal
Memorial Sloan Kettering Cancer Center
Sanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaborators

Active, not recruiting

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

United States
Fondazione EMN Italy Onlus

Active, not recruiting

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Multiple Myeloma

Italy
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; University of Washington; H. Lee...

Active, not recruiting

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

T Cell Non-Hodgkin Lymphoma

United States
Fondazione EMN Italy Onlus

Active, not recruiting

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients (MPRvsMEL200)

Multiple Myeloma | Newly Diagnosed Patients

Italy
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
University of California, San Diego
National Cancer Institute (NCI)

Terminated

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Breast Cancer

United States
Centre Hospitalier Universitaire de Saint Etienne
Institut de Cancérologie de la Loire

Completed

High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment (IRMYG)

Multiple Myeloma | Renal Failure

France, Belgium, Algeria, Lebanon
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Terminated

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma (GEMHDM2014)

Follicular Lymphoma | Hodgkin's Lymphoma - Relapsed/Refractory | Non-Hodgkin's Lymphoma - Aggressive

Canada
Dana-Farber Cancer Institute
Entrinsic Health

Completed

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma

Multiple Myeloma | Non-Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center

Terminated

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

T-cell Non-Hodgkin Lymphoma

United States
Hackensack Meridian Health
Millennium Pharmaceuticals, Inc.

Completed

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT (Thal/Mel/Vel)

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Multiple Myeloma

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC; Multiple Myeloma Research...

Terminated

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Multiple Myeloma

United States
Hackensack Meridian Health

Completed

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma (Mel-Vel)

Multiple Myeloma

United States
University of Illinois at Chicago

Completed

Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03) (BMT-03)

Multiple Myeloma, Relapsed | Multiple Myeloma, Refractory to Standard Treatment

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
University of Southampton
NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation... and other collaborators

Terminated

High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant (AntiCD-66)

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
Boston Medical Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Amyloidosis

United States
M.D. Anderson Cancer Center

Completed

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Myeloma

United States
Acrotech Biopharma Inc.
Clinipace Worldwide; Beckloff Associates, Inc.; Kansas City Bioanalytical Laboratories

Completed

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Myeloma

United States
M.D. Anderson Cancer Center

Completed

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Leukemia | Hematologic Malignancies | Blood Stem Cell Transplant Failure

United States
BioInvent International AB

Terminated

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | CD19 Positive

United States
M.D. Anderson Cancer Center

Completed

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Lymphoma

United States
Washington University School of Medicine

Terminated

A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

Multiple Myeloma

United States
Attaya Suvannasankha
Celgene

Completed

Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
University of Illinois at Chicago

Terminated

Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma (BMT-02)

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Tufts Medical Center; Lahey Clinic

Completed

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Multiple Myeloma

United States
Centre Leon Berard

Terminated

BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) (BENEFIT)

Follicular Lymphoma

France

Search clinical trials for: High dose Melphalan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations